Company / Accounts Receivable
Wave Life Sciences Ltd. Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.3M
FY2025
5-year range
$1.3M / $21.1M
FY2021-FY2025
Trend
-10.3%
vs FY2024
Sector context
#104 of 113
Health Care
What the data says
Among 113 Health Care companies, Wave Life Sciences Ltd. is in the bottom 8% for accounts receivable. Accounts Receivable has declined for 3 consecutive years, from $30M in FY2020 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -46.8%.
Declined from $21M to $1M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -46.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 113This company $1.3M Sector average $1.1B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -46.8%, indicating a declining trend.
- In FY2025, accounts receivable decreased 10.3% year-over-year.
- Ranks #104 out of 113 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | -10.3% |
| FY2024 | $1.4M | -93.3% |
| FY2023 | $21.1M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $30.0M | +50.0% |
| FY2019 | $20.0M | +100.0% |
| FY2018 | $10.0M | +900.0% |
| FY2017 | $1.0M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026